These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 23998969)

  • 1. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
    Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
    J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
    Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
    Mozaffarian D; Maki KC; Bays HE; Aguilera F; Gould G; Hegele RA; Moriarty PM; Robinson JG; Shi P; Tur JF; Lapointe JF; Aziz S; Lemieux P;
    JAMA Netw Open; 2022 Jan; 5(1):e2141898. PubMed ID: 34989797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Jun JE; Jeong IK; Yu JM; Kim SR; Lee IK; Han KA; Choi SH; Kim SK; Park HK; Mok JO; Lee YH; Kwon HS; Kim SH; Kang HC; Lee SA; Lee CB; Choi KM; Her SH; Shin WY; Shin MS; Ahn HS; Kang SH; Cho JM; Jo SH; Cha TJ; Kim SY; Won KH; Kim DB; Lee JH; Lee MK
    Diabetes Metab J; 2020 Feb; 44(1):78-90. PubMed ID: 31237134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
    Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
    J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
    Offman E; Marenco T; Ferber S; Johnson J; Kling D; Curcio D; Davidson M
    Vasc Health Risk Manag; 2013; 9():563-73. PubMed ID: 24124374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
    Dogay Us G; Mushtaq S
    Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial.
    Stroes ESG; Susekov AV; de Bruin TWA; Kvarnström M; Yang H; Davidson MH
    J Clin Lipidol; 2018; 12(2):321-330. PubMed ID: 29289538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
    Davidson MH; Phillips AK; Kling D; Maki KC
    Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1045-54. PubMed ID: 25089906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
    Roth EM; Bays HE; Forker AD; Maki KC; Carter R; Doyle RT; Stein EA
    J Cardiovasc Pharmacol; 2009 Sep; 54(3):196-203. PubMed ID: 19597368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
    Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
    Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
    Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J
    Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
    Nicholls SJ; Lincoff AM; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Pedersen TR; Ridker PM; Ray K; Karlson BW; Lundström T; Wolski K; Nissen SE
    Clin Cardiol; 2018 Oct; 41(10):1281-1288. PubMed ID: 30125052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
    Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States.
    Lapointe JF; Harvey L; Aziz S; Jordan H; Hegele RA; Lemieux P
    Clin Ther; 2019 Mar; 41(3):426-444. PubMed ID: 30799231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
    Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
    Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.